The Future is CBD and (OTC: NWPN) Looks Set to Explode!

[Image](?awt_a=1jS4A&awt_l=Dx3Vy&awt_m=gOI3X9RVlAvde4A) [Image]( The Now Company (OTC: NWPN) shares could DOUBLE as company aims to dominate the CBD space! The biggest hurdle facing marijuana stocks has always been legalization. Despite several U.S. states have taken steps to legalize the drug, the federal government still treats it as criminal. This may not last much longer as the U.S. House is expected to vote for the very first time on legalizing the drug on a federal level. Marijuana related stocks like The Now Company (OTC: NWPN) may be poised for dramatic upside as this historical vote could be a catalyst to set off a major rally in the arena! NWPN is dedicated to advancing the study of the medicinal use of Cannabidiol (CBD) and other cannabinoid molecules and seeks to develop cannabis-derived therapeutic products backed by strict and ethical scientific research. According to the National Retail Federation, the CBD industry grew in customer demand by a whopping 700 percent in 2019. CBD sales are expected to reach $4 billion dollars by 2023 says the Nutrition Business Journal! [Check out why NWPN could skyrocket as the future awaits a CBD profit wave!]( [Our Exclusive Report On:]( [Image](?awt_a=1jS4A&awt_l=Dx3Vy&awt_m=gOI3X9RVlAvde4A) www.thenowcorp.net In the midst of growing worldwide interest in medicinal cannabis, NWPN is lighting up on Wall Street with enormous profit potential ahead! With the 2018 Farm Bill that was passed in December 2018, industrial hemp in the United States became federally legalized. This means that hemp is no longer regulated as an illegal substance under the US Justice Department and this is greatly benefiting the CBD industry. According to New Frontier Data: China led all countries with nearly $1.2 billion USD in hemp sales in 2018, followed by the United States ($1.0 billion), Europe ($980 million) and South and Central America ($220 million). The U.S. market is positioned to grow under the 2018 Farm Bill, with an estimated $2.6 billion projected in sales by 2022, with $1.3 billion in sales estimated for hemp-derived CBD products by 2022! According to the National Retail Federation, the CBD industry grew in customer demand by a whopping 700 percent in 2019. CBD sales are also expected to reach $4 billion dollars by 2023 says the Nutrition Business Journal. The public awareness of CBD and its many natural benefits is exploding and CBD products are flooding the market. As CBD becomes legal and more available throughout the US, increased government regulation is inevitable! NWPN is well positioned to capitalize on the emerging opportunities resulting from the need for more research studies, product testing, hemp cultivation and production, product development, and education! On November 19, 2019, The FDA warned 15 companies for illegally selling various products containing cannabidiol as the agency details safety concerns. Violations included marketing unapproved new human and animal drugs, selling CBD products as dietary supplements, and adding CBD to human and animal foods. These are concerning issues that take place in the marijuana industry and through the company's research, NWPN will address such safety concerns by performing rigorous testing of CBD compounds. By publishing a scientific white paper based on the study, it will additionally allow the FDA to review the information and have credible data to make concrete rulings. While the industry is big, safety concerns are still prevalent creating a demand for the type of research NWPN is involved with. NWPN is dedicated to advancing the study of the medicinal use of Cannabidiol (CBD) and other cannabinoid molecules and seeks to develop cannabis-derived therapeutic products backed by strict and ethical scientific research. In an effort to uncover the potential therapeutic capacity of cannabinoids, the company looks to establish the safest and most effective route of administration of highly purified CBD which currently remains to be determined within scientific literature. NWPN has created agreements with top research scientists from major Universities and have utilized their existing labs to perform expensive research using cannabinoid compounds. From the research, the company will be able to publish research white papers that will contain credible data from these research laboratories. As a result, the information that NWPN publishes will start to establish increased credibility in the industry, and will allow the company's products to be prescribed by physicians since they will be able to access the information in their databases. These studies will answer many questions and stop false data and rumors about CBD/THC derived from cannabis, and the effects on the human body. NWPN has signed a joint venture with Hollywood Diagnostics Center to perform neurological studies using state-of-the-art imaging technology to measure brain activity by detecting changes associated with blood flow when CBD compounds are introduced to the human body. [Image](?awt_a=1jS4A&awt_l=Dx3Vy&awt_m=gOI3X9RVlAvde4A) Hollywood Diagnostics Center is a leader in the medical diagnostics field while performing over 30,000 diagnostic procedures annually! The center continues to be at the forefront of medical technology by progressively updating its equipment and procedures to reflect the latest advances in medicine. HDC has provided the healthcare community with outstanding, technologically advanced medical services to address the changing needs of patients. The goal of the imaging data analysis is to detect correlations between brain activation in subjects when either non-tasked or tasked activities are performed during the scan with CBD compounds present. It also aims to discover correlations with cognitive states after CBD compounds are introduced to the subject. NWPN additionally is aiming to work with both NASA and SpaceX for its research initiatives! Concerning NASA, the company would like to utilize the International Space Station for unique discoveries of how CBD and THC reacts using animal testing. Cells tend to have a different effects in zero gravity. Concerning SpaceX, they are aggressive in taking humans to space, for long extended times, and eventually to Mars. Through the company's research initiatives, the creation of an organic CBD nausea drug would be safe and beneficial for astronauts. NWPN desires to have an FDA approved medicine that focuses on nausea and other ailments. Due to the FDA approval, it will be available for pharmacies to dispense, and will be on the approved list for insurance companies to pay for. Ultimately, the company will pursue patenting the compound on a molecular level, similar to Pfizers patent on the drug, Viagra. Nausea and vomiting are not diseases, but they are symptoms of many conditions such as: Motion sickness or seasickness. Early stages of pregnancy (nausea occurs in approximately 50%-90% of all pregnancies; vomiting in 25%-55%). This makes the market for an anti-nausea medicine significant! One reason to closely follow NWPN is because of big pharma... Big pharma is definitely recognizing the very lucrative opportunity when it comes to medicinal marijuana. Cannabis is inexpensive to produce, and with the right policies, there could be widespread access to those in need, which disrupts the traditional marketplace. A recent report found that Big Pharma stands to lose as much as $4 billion per year if medical marijuana became legal in all 50 states. The information is based off a study from 2016 by the University of Georgia, which found that states with legalized medicinal cannabis had less Medicare prescriptions than those where it's still illegal. The study found that already pharmaceutical companies are losing $166 million annually on drugs where marijuana is now offered as an alternative. Big pharma will have no choice but to jump onto the cannabis bandwagon if they want to continue capitalizing on patients! GW Pharmaceuticals did and in the summer of 2018, Epidiolex became the first FDA-approved plant-derived cannabinoid medicine available by prescription in the U.S. to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. Epidiolex brought in $104 million in net sales in the fourth quarter and a total of $296 million in 2019 across the globe! Pharmaceutical giants are already preparing for the cannabis revolution and are building connections. Plus with the rise in opioid lawsuits, it may lead to many drug companies looking to cannabinoids in the search for less-addictive pain relievers. This will only further fuel the momentum of the cannabis revolution and these pharma giants could be going on shopping sprees to scoop up smaller players such as NWPN! Many of you may know that there is a growing problem with fossil fuel depletion. As the price at the pumps continue to rise, the law of supply and demand, as well as many top analysts predict our crude oil resources are running out. Crude oil is not a renewable resource, so once it’s gone… well, that's it. This is why hemp biofuel is looking like an attractive alternative and NWPN could soon get recognized for its pilot program for producing derivatives from Industrial Hemp for biodiesel fuel in North Dakota! The company has an interest in the Hemp biofuel industry to provide a renewable alternative energy solution. With respect to furtherance of this goal, the company looks to employ advanced chemistry research and technologies to elucidate the biological Hemp molecules to advance quality and effectiveness of the biofuel. North America has absolutely no problem extracting oil from Hemp seeds which the company can subsequently use to make biofuel. The Industrial Hemp farming industry is capable of bringing the United States 100% clean, renewable energy and NWPN could be at the forefront of this emerging space! The ignorant perception surrounding cannabis is continuing to fade. No longer is marijuana looked at as the stoner's legacy! The reality is that this fascinating plant has the potential to reduce human and animal suffering on a magnificent level! Cannabis is known for its medicinal qualities and health benefits that include relieving insomnia, anxiety, spasticity, and pain to even treating potentially life-threatening conditions such as diabetes, epilepsy, and cancer. Members of the US House of Representatives are expected to vote later this month on The Marijuana Opportunity, Reinvestment, and Expungement Act... otherwise known as The MORE Act. This is HUGE as it is the very first time that the U.S. House will vote on federal marijuana legalization! NWPN could be gearing up for a big rally as the U.S. finally pushes forward with federal marijuana legislation. Plus with everything the company is involved with, this is looking like a ground-floor situation that may not remain off of Wall Street's radar much longer! Especially as NWPN's CEO Ken Williams has spent five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an executive for multi-million-dollar brands! [The Now Corporation (OTC: NWPN) looks poised to separate itself from all the rest... make sure you have the stock on your watchlist!]( EMAIL}/redirect GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY THE FOLLOWING NOTICE AND DISCLAIMER MUST BE READ AND UNDERSTOOD AND YOU MUST AGREE TO THE TERMS CONTAINED THEREIN BEFORE USING THIS WEBSITE OR SUBSCRIBING TO OUR NEWSLETTER. We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of DearWallstreet.com nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on DearWallstreet.com. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. DearWallstreet.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. DearWallstreet.com has been retained by an unrelated third party to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from such third party. Questions regarding this website may be sent to info@DearWallstreet.com. Some of the content on this website contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of a company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results. Generally, the information regarding a company profiled or discussed on this website is provided from public sources. DearWallstreet.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and DearWallstreet.com has no obligation to update any of the information provided. DearWallstreet.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. DearWallstreet.com encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content. DearWallstreet.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does DearWallstreet.com control, endorse, or guarantee any content found in such sites. DearWallstreet.com does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that DearWallstreet.com, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that DearWallstreet.com, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. DearWallstreet.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm. Income Disclaimer: Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions. DearWallstreet.com has been paid up to $100,000 in cash compensation from Electrik Dojo LLC for this profile of The Now Corporation (OTC: NWPN) which services include the issuance of this release and other opinions that we release concerning The Now Corporation (OTC: NWPN). DearWallstreet.com has not investigated the background of Electrik Dojo LLC, the hiring party, or The Now Corporation (OTC: NWPN). Anyone viewing this newsletter should assume Electrik Dojo LLC or affiliates of Electrik Dojo LLC, own shares of the The Now Corporation (OTC: NWPN) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. DearWallstreet.com has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding The Now Corporation (OTC: NWPN). Rua Frei Tomé de Jesus n. 18 1 dto. Lisboa Lisboa 1700-215 PORTUGAL [Unsubscribe]( | [Change Subscriber Options](